miR-125a regulates cell cycle, proliferation, and apoptosis by targeting the ErbB pathway in acute myeloid leukemia.

Document Type

Article

Publication Date

3-1-2014

Institution/Department

Molecular Medicine; MMCRI

Journal Title

Leukemia research

MeSH Headings

Animals, Antimetabolites, Antineoplastic, Apoptosis, Azacitidine, Cell Cycle, Cell Proliferation, CpG Islands, Gene Expression Regulation, Leukemic, Hematopoiesis, Humans, Leukemia, Myeloid, Acute, Mice, Mice, Inbred NOD, MicroRNAs, Oncogene Proteins v-erbB, Signal Transduction

Abstract

microRNA profiling of acute myeloid leukemia patient samples identified miR-125a as being decreased. Current literature has investigated miR-125a's role in normal hematopoiesis but not within acute myeloid leukemia. Analysis of the upstream region of miR-125a identified several CpG islands. Both precursor and mature miR-125a increased in response to a de-methylating agent, Decitabine. Profiling revealed the ErbB pathway as significantly decreased with ectopic miR-125a. Either ectopic expression of miR-125a or inhibition of ErbB via Mubritinib resulted in inhibition of cell cycle proliferation and progression with enhanced apoptosis revealing ErbB inhibitors as potential novel therapeutic agents for treating miR-125a-low AML.

ISSN

1873-5835

First Page

402

Last Page

410

Share

COinS